Saphnelo (anifrolumab-fnia) - AstraZeneca
Multicenter Real-World Registry of Anifrolumab (ANIFRO-REU) in Systemic Lupus Erythematosus: Effectiveness in Patients with Articular and Cutaneous Manifestations with up to 12 Months of Follow-up (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2215; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available 
Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
https://eppro02.ativ.me/web/page.php?nav=false&page=Session&project=ACR26&id=3570111
 
Irene Carrión-Barberà
 
Sep 8, 2026
 
Prev Next